Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | HEXA | P06865 | 1/20 | 0.33 |
| ▸ | HEXB | P07686 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | JUN | P05412 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10307332 | 0.83 | HSP90AA1 (0.36) | MAPKAPK2ALDH1A1PDK2PDK4HSP90AA1 | |
| SCHEMBL30689655 | 0.83 | HSP90AA1 (0.36) | MAPKAPK2ALDH1A1PDK2PDK4HSP90AA1 | |
| SCHEMBL25346557 | 0.79 | ALDH1A1 (0.41) | MAPKAPK2ALDH1A1 | |
| SCHEMBL5231805 | 0.78 | MAPKAPK2 (0.39) | MAPKAPK2ALDH1A1PDK2PDK4HSP90AA1 | |
| SCHEMBL17765160 | 0.78 | MAPKAPK2 (0.56) | MAPKAPK2HEXAHEXB | |
| SCHEMBL19704109 | 0.78 | MAPKAPK2 (0.39) | MAPKAPK2ALDH1A1PDK2PDK4HSP90AA1 | |
| SCHEMBL23214613 | 0.78 | ALDH1A1 (0.39) | MAPKAPK2ALDH1A1 | |
| SCHEMBL23694612 | 0.78 | ALDH1A1 (0.39) | MAPKAPK2ALDH1A1 | |
| SCHEMBL511539 | 0.78 | NOS3 (0.37) | MAPKAPK2PDK2PDK4HSP90AA1DHFR | |
| Pyrazine SCHEMBL10348783 | 0.77 | HSP90AA1 (0.33) | HSP90AA1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1619948-A4 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060247245-A1 | Substituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands | NEUROGEN CORPORATION | 2006-11-02 | — | — | US | disclosed |
| EP-1619948-A1 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004107863-A1 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247245-A1 | Substituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands | GABRA5, GABRA3, GABRA2 | MAPKAPK2 4054/4885ALDH1A1 1215/4885PDK2 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.